Bayer's Pipeline Wins an FDA Nod While a Missouri Judge Holds the Wildcard

Bayer's Hyrnuo wins FDA accelerated approval for HER2-mutated lung cancer, while a Missouri court weighs final approval of the glyphosate settlement.

Bayer's oncology franchise picked up a notable regulatory win this month, but the market's attention remains fixed on a courtroom in Missouri — a split-screen that neatly captures where the Leverkusen group stands roughly two-thirds of the way through 2026.

The U.S. Food and Drug Administration granted accelerated approval to Hyrnuo, the company's drug candidate containing the active ingredient sevabertinib, clearing it for use as a first-line therapy in adults with locally advanced or metastatic HER2-mutated non-small cell lung cancer. The decision, announced September 9, came through a priority review pathway and rests on data from the Phase I/II SOHO-01 trial.

A 75% Response Rate in the Spotlight

Results from cohort F of that study, which enrolled 69 patients, showed an objective response rate of 75%. Four participants achieved a complete remission, while 48 others recorded a partial response. For Bayer, the green light reinforces an oncology pipeline in one of the most hotly contested indication areas in medicine.

The approval lands alongside other recent pipeline momentum. Roughly two weeks ago, Bayer filed for approval of Kerendia in Japan as a treatment for non-diabetic chronic kidney disease. Subgroup analyses from the FIND-CKD study, also presented about a fortnight ago, indicated that finerenone slows kidney function loss in patients with hypertensive nephropathy.

On the commercial side, Kerendia revenues climbed 75% to EUR 603 million in the first half of 2026, underscoring the kind of top-line traction management hopes to replicate with newer launches.

Balance Sheet Gets a EUR 3 Billion Boost

While the science advances, Bayer is simultaneously reshaping its capital structure. A transaction with Apollo funds covering the long-acting contraceptive business will inject EUR 3.0 billion of equity into the group in exchange for a minority stake in a newly created subsidiary. Closing is targeted for the third quarter of 2026.

That deal prompted management to lower its full-year 2026 net financial debt guidance to a range of EUR 29 billion to EUR 30 billion, down from the previous EUR 32 billion to EUR 33 billion target.

The move sits atop a steady operating base. Group-wide, currency- and portfolio-adjusted sales rose 3.3% to EUR 24.277 billion in the first half of 2026. Operating profit before special items advanced 6.6% to EUR 6.597 billion, and adjusted core earnings per share came in at EUR 3.66. For the full year, Bayer reaffirmed its forecast of adjusted EBITDA between EUR 9.6 billion and EUR 10.1 billion.

The Missouri Hearing and the Legal Overhang

Yet the legal legacy refuses to fade. The hearing on final approval of the glyphosate settlement package took place last Monday before the relevant court in Missouri. Until that matter reaches a binding conclusion, litigation developments are likely to keep shaping sentiment around the stock.

Bayer has already secured some legal tailwinds. A U.S. Supreme Court ruling on June 25, decided 7-2, affirmed the primacy of federal requirements over state law. On August 27, the Eighth Circuit Court of Appeals rejected an objection in the matter. Should the Missouri judge grant final approval, it would effectively close the book on a large share of the U.S. claims.

The pipeline build-out extends beyond the courtroom, too. In May 2026, Bayer agreed to acquire Perfuse Therapeutics for up to USD 2.45 billion — comprising a USD 300 million upfront payment plus milestone-based consideration — strengthening its ophthalmology development portfolio.

Where the Stock Stands

Shares closed yesterday at EUR 48.69, off 1.4%. Despite near-term swings, the stock has gained 32% since the start of the year, a run that reflects the market's early credit for the consolidation strategy.

The bull case hinges on the debt-reduction measures clicking into place while the pharma division monetizes its recent wins — the added U.S. indication for Hyrnuo opening near-term revenue in a specialized oncology niche, with net debt potentially pushed below EUR 30 billion and the valuation discount to European chemical and pharma peers narrowing as a result.

The bear case is equally clear. If the Missouri court imposes additional conditions on final settlement approval or allows new appeals, legal uncertainty stays a permanent companion — tying up management bandwidth and keeping the risk premium elevated. Commercialization risk in the lung cancer segment remains, since new therapies must first establish themselves against existing standards of care. Japan's regulatory review of Kerendia is no formality either. And any delay to the EUR 3.0 billion Apollo transaction beyond the current quarter would push the projected debt reduction further out, leaving interest costs on the group's income statement for longer than planned.

Two catalysts now loom largest: the Missouri court's pending ruling on final approval of the glyphosate settlement, and confirmation that the Apollo deal reaches financial closing before the quarter ends.